IgG Antibodies to GlcNAcβ and Asialo-GM2 (GA2) Glycans as Potential Markers of Liver Damage in Chronic Hepatitis C and the Efficacy of Antiviral Treatment

Table 3

Association of the level of anti-GlcNAcβ Abs and ALP with the stages of fibrosis.

Parameter	Genotype	Stage ()	Median ()
Anti-GlcNAcβ	1b	0	0.155
		1–3	0.377	0.055 (F0 vs. F1–3)
		1–4	0.389	0.021 (F0 vs. F1–4)
ALP	1b	0	67
		1–4	80	0.025 (F0 vs. F1–4)
		0–1	67
		2–4	86	0.002 (F0–1 vs. F2–4)
	1b and 3a	0	67
		1–4	81	0.008 (F0 vs. F1–4)
		0–1	68
		2–4	86	0.001 (F0–1 vs. F2–4)